The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
Abstract
Background & aims Around 10-20% of patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The benefit of weight reduction in such patients is unclear. We aim to study the efficacy of lifestyle intervention in non-obese patients with NAFLD and to identify factors that predict treatment response.Methods A total of 154 community NAFLD patients were randomised to a 12-month lifestyle intervention programme involving regular exercise, or to standard care. The primary outcome was remission of NAFLD at Month 12 by proton-magnetic resonance spectroscopy. After the programme, the patients were prospectively followed until Year 6. The Asian body mass index (BMI) cut-off of 25 kg/m 2 was used to define non-obese NAFLD.Results Patients were assigned to the intervention (n = 77) and control (n = 77) groups (39 and 38 in each group had baseline BMI <25 and ≥25 kg/m 2, respectively). More patients in the intervention group achieved the primary outcome than the control group regardless of baseline BMI (non-obese: 67% vs. 18%, p <0.001; obese: 61% vs. 21%, p <0.001). Lifestyle intervention, lower baseline intrahepatic triglyceride, and reduction in body weight and waist circumference were independent factors associated with remission of NAFLD in non-obese patients. Half of non-obese patients achieved remission of NAFLD with 3-5% weight reduction; the same could only be achieved in obese patients with 7-10% weight reduction. By Year 6, non-obese patients in the intervention group remained more likely to maintain weight reduction and alanine aminotransferase normalisation than the control group.Conclusions Lifestyle intervention is effective in treating NAFLD in both non-obese and obese patients. Weight reduction predicts remission of NAFLD in non-obese patients, but a modest weight reduction may be sufficient in this population.Lay summary Some patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The optimal management of such patients is unclear. In this long-term follow-up study of a clinical trial, we show that remission of NAFLD can be achieved in 67% of non-obese patients after lifestyle intervention. The majority of patients can achieve NAFLD remission with modest weight loss of 3-10%. Non-obese patients are also more likely than obese patients to maintain weight reduction and normal liver enzymes in the long run.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an RCT of a 12month lifestyle intervention programme, a 3-5% weight reduction led to remission of MASLD (measured by 1 H-MRS) among 50% of the individuals without obesity.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [333]
In the citing paper
“Moreover, individuals de fi ned as non-obese were more likely than individuals with obesity to maintain weight reduction and normal liver enzymes over long-term (6-year) follow-up. 333”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [333]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,146
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term weight loss maintenance
Wing, R. R., & Phelan, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.222s · Cited by 1,941
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322
Cited by
Sorted by citations
Items 101–200 of 319
Mouskeftara, T., Deda, O., Papadopoulos, G., Chatzigeorgiou, A., & Gika, H. (2024) · Molecules · doi:10.3390/molecules29071494 · Cited by 27
Li, F., Zhang, Z., Bai, Y., Che, Q., Cao, H., Guo, J., & Su, Z. (2023) · Molecules · doi:10.3390/molecules28196918 · Cited by 27
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Chan, W., Petta, S., Noureddin, M., Goh, G. B., & Wong, V. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17866 · Cited by 25
Nguyen, V. H., Yeo, Y. H., Zou, B., Le, M. H., Henry, L. L., Cheung, R. C., & Nguyen, M. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13203 · Cited by 25
Torres, S., Brol, M. J., Magdaleno, F., Schierwagen, R., Uschner, F. E., Klein, S., Ortiz, C., Tyc, O., Bachtler, N., Stunden, J., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.715765 · Cited by 25
Wei, L.-M., Cheng, X., Luo, Y., Yang, R., Lei, Z., Jiang, H., & Chen, L. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.008 · Cited by 18
Current strategies for nonalcoholic fatty liver disease treatment (Review)
Sun, J., Jin, X., & Li, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5412 · Cited by 27
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
Bai, W., & Zhu, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1720780 · Cited by 34
Ma, Q., Liao, X., Shao, C., Lin, Y., Wu, T., Sun, Y., Feng, S., Ye, J., & Zhong, B. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01790-w · Cited by 24
Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations
Zelber‐Sagi, S. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1729971 · Cited by 23
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 25
An, J., & Sohn, J. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0437 · Cited by 24
Lara, C., & Romero‐Gómez, M. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.34 · Cited by 22
Abassi, W., Ouerghi, N., Hammami, M. B., Jebabli, N., Feki, M., Bouassida, A., Weiss, K., & Knechtle, B. (2025) · Nutrients · doi:10.3390/nu17010164 · Cited by 23
Ivashkin, V. T., Drapkina, O. M., Maevskaya, M. V., Raikhelson, K. L., Okovityi, S. V., Жаркова, М. С., Grechishnikova, V. R., Abdulganieva, D. I., Alekseenko, S. A., Ardatskaya, M. D., et al. (2025) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2025-35-1-94-152 · Cited by 29
Ultrasound-based hepatic fat quantification: current status and future directions
Seneviratne, N., Fang, C., & Sidhu, P. S. (2022) · Clinical Radiology · doi:10.1016/j.crad.2022.10.003 · Cited by 23
Duseja, A. K., De, A., & Wong, V. W. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.011 · Cited by 23
Ge, X., Wang, X., Yan, Y., Zhang, L., Yu, C., Lu, J., Xu, X., Gao, J., Liu, M., Jiang, T., et al. (2023) · Liver International · doi:10.1111/liv.15588 · Cited by 23
Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective
Yu, B. C.-Y., Kwok, D., & Wong, V. W. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.01.007 · Cited by 24
Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease
Zhou, R., Gu, Y., Zhang, B., Kong, T., Zhang, W., Li, J., & Shi, J. (2023) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000575 · Cited by 21
Chen, Y., Chen, T., Yin, S., Huang, C., Huang, J., Lu, S., Yeh, M., Huang, C., Dai, C., Chen, Y., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16592 · Cited by 21
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Fouad, Y., Saad, Z., Abdelraheem, E. M., Gany, Y. A., Moness, H., Osman, N., Abdelhameed, W., Mostafa, A., & Attia, D. (2020) · medRxiv · doi:10.1101/2020.08.20.20176214 · Cited by 23
Chang, X., Shi, Y., Wang, J., Liu, H., Chen, Y., Zhu, X., Chen, Y., Yu, Z., Shang, Q.-H., Tan, L., et al. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.06.009 · Cited by 20
Kim, H. Y., Baik, S. J., Lee, H. A., Lee, B. K., Lee, H. S., Kim, T. H., & Yoo, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-74659-9 · Cited by 20
Njei, B. M., Ameyaw, P. A., Al‐Ajlouni, Y. A., Njei, L., & Boateng, S. (2024) · Cureus · doi:10.7759/cureus.71451 · Cited by 24
Michel, M. S., & Schattenberg, J. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1716333 · Cited by 19
Association between longitudinal weight change and clinical outcome in individuals with MASLD
Shi, Y., Zhou, R., Kim, S. U., Yip, T. C., Tsochatzis, E. A., Petta, S., Nakajima, A., Hagström, H., Bugianesi, E., Chan, W., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001557 · Cited by 18
Ganjooei, N. A., Jamialahmadi, T., Nematy, M., Jangjoo, A., Goshayeshi, L., Khadem‐Rezaiyan, M., Reiner, Ž., Alidadi, M., Markin, A. M., & Sahebkar, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.682352 · Cited by 19
Chang, Y., Jeon, J., Song, T.-J., & Kim, J. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07370-x · Cited by 20
Ma, Q., Ye, J., Shao, C., Lin, Y., Wu, T., & Zhong, B. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221122426 · Cited by 19
Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a
Wang, Z., Zhu, Y., Xia, L., Li, J., Song, M., & Yang, C. (2022) · Nutrients · doi:10.3390/nu15010121 · Cited by 18
Pathobiology of Metabolic-Associated Fatty Liver Disease
Fouda, S., Jeeyavudeen, M. S., Pappachan, J. M., & Jayanthi, V. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.001 · Cited by 20
Current treatment options for nonalcoholic fatty liver disease
Shetty, A., & Syn, W. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000528 · Cited by 19
Qi, Y., Fan, L., Ran, D., Xu, J., Wang, Y., Wu, J., & Zhang, Z. (2021) · Journal of Oncology · doi:10.1155/2021/7764817 · Cited by 18
Sequential drug delivery for liver diseases
Huang, X., Lee, F., Teng, Y., Lingam, C. B., Chen, Z., Sun, M., Song, Z., Balachander, G. M., Leo, H. L., Guo, Q., et al. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.001 · Cited by 18
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong, G., Dashti, F., & Banini, B. A. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15012 · Cited by 18
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Chui, Z. S. W., Xue, Y., & Xu, A. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 21
Chang, Q., Zhang, Y., Zhang, T., Liu, Z., Cao, L., Zhang, Q., Liu, L., Sun, S., Wang, X., Zhou, M., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0133 · Cited by 18
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Hanif, H., Khan, M. M., Ali, M. J., Shah, P. A., Satiya, J., Lau, D., & Aslam, A. (2020) · Microorganisms · doi:10.3390/microorganisms8101526 · Cited by 17
Cinque, F., Cespiati, A., Lombardi, R., Costantino, A., Maffi, G., Alletto, F., Colavolpe, L., Francione, P., Oberti, G., Fatta, E., et al. (2022) · Nutrients · doi:10.3390/nu14030556 · Cited by 17
Cong, F., Zhu, L., Deng, L., Xue, Q., & Wang, J. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02708-4 · Cited by 17
Principles of Nutritional Management in Patients with Liver Dysfunction—A Narrative Review
Elsebaie, E. M., Abdel-Fattah, A. N., Bakr, N. A., Attalah, K. M., & Aweas, A.-H. A. (2023) · Livers · doi:10.3390/livers3020013 · Cited by 19
Nutritional and Lifestyle Therapy for NAFLD in People with HIV
Cinque, F., Cespiati, A., Lombardi, R., Guaraldi, G., & Sebastiani, G. (2023) · Nutrients · doi:10.3390/nu15081990 · Cited by 19
Barrón‐Cabrera, E., Soria-Rodriguez, R. A., Amador-Lara, F., & Martínez‐López, E. (2023) · Healthcare · doi:10.3390/healthcare11141992 · Cited by 18
Metabolic dysfunction associated fatty liver disease in healthy weight individuals
Méndez‐Sánchez, N., Brouwer, W. P., Lammert, F., & Yilmaz, Y. N. (2024) · Hepatology International · doi:10.1007/s12072-024-10662-w · Cited by 16
Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease
Seko, Y., Lin, H., Wong, V. W., & Okanoue, T. (2024) · Liver International · doi:10.1111/liv.16164 · Cited by 16
Wong, V. W., Neff, G. W., Bisceglie, A. M. D., Bai, R., Cheng, J., Meng, Y., Liberman, A., Liu, L., & Gunn, N. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0145 · Cited by 15
Ling, Z., Zhang, C., He, J., Ouyang, F., Qiu, D., Li, L., Li, Y., Li, X., Duan, Y., Luo, D., et al. (2023) · Nutrients · doi:10.3390/nu15030604 · Cited by 15
Pais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.014 · Cited by 15
Huang, Y., Xu, J., Yang, Y., Wan, T., Wang, H., & Li, X. (2024) · Nutrients · doi:10.3390/nu16132063 · Cited by 15
S2k-Leitlinie Klinische Ernährung in der Hepatologie
Plauth, M., Bechmann, L. P., Grajecki, D., Gundling, F., Kramer, L., Kremer, A. E., Rau, M., Schneider, A., Tacke, F., & van Thiel, I. (2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2338-1144 · Cited by 14
Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
Torosian, K., Lal, E., Kavanaugh, A., Loomba, R. S., Ajmera, V. H., & Gumá, M. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152165 · Cited by 15
You, Y., Huang, Y., Wang, X., Ni, H., Ma, Q., Ran, H., Cai, J., Lin, X., Luo, T., Wu, C., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.04.029 · Cited by 14
Li, J., Huang, L., Xiong, W., Qian, Y. X., & Song, M. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.03.008 · Cited by 14
Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD
Schnurr, T. M., Katz, S. F., Justesen, J. M., O’Sullivan, J. W., Saliba‐Gustafsson, P., Assimes, T. L., Carcamo‐Orive, I., Ahmed, A., Ashley, E. A., Hansen, T. F., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1932 · Cited by 14
Weigh change across adulthood is related to the presence of NAFLD: results from NHANES III
Wang, L., Yi, J., Guo, J., & Ren, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04007-8 · Cited by 14
Wang, X., Jin, X., Li, H., Zhang, X., Chen, X., Lu, K., & Chu, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180016 · Cited by 17
Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?
Kawaguchi, T., & Torimura, T. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01650-1 · Cited by 14
Azulai, S., Grinbaum, R., Beglaibter, N., Eldar, S. M., Rubin, M., Ben-Haroush Schyr, R., Romano-Zelekha, O., & Ben-Zvi, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051144 · Cited by 13
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
Nonalcoholic Fatty Liver Disease
Yip, T. C., Wong, G. L., Wong, V. W., Goh, G. B., & Chan, W. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.12.003 · Cited by 15
The metabolic profiles and body composition of non-obese metabolic associated fatty liver disease
Zhang, Y., Xiang, L.-L., Qi, F., Cao, Y.-T., Zhang, W., Lv, T.-S., & Zhou, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1322563 · Cited by 13
Brodosi, L., Stecchi, M., Musio, A., Bazzocchi, M., Risi, E., Marchignoli, F., Marchesini, G., & Petroni, M. L. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02287-0 · Cited by 16
Ala, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15
Alonso‐Peña, M., Barrio, M. D., Peleteiro‐Vigil, A., Jiménez-González, C., Santos‐Laso, Á., Arias, M., Iruzubieta, P., & Crespo, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310718 · Cited by 16
Predicting NASH response with liver fat: Are we back to square one?
Wong, V. W. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.024 · Cited by 13
Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions
Chan, W., & Wong, V. W. (2022) · Liver International · doi:10.1111/liv.15142 · Cited by 13
Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link
Effenberger, M., Grander, C., Grabherr, F., & Tilg, H. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00069 · Cited by 14
Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications
Tidwell, J., & Wu, G. Y. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00252 · Cited by 12
Yuan, H., Tong, X., Ren, Y., Li, Y., Wang, X., Chen, L., Chen, S., Jin, X., Wang, X., Targher, G., et al. (2024) · Liver International · doi:10.1111/liv.16025 · Cited by 12
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 13
The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease
Kim, A., Krishnan, A., Hamilton, J. P., & Woreta, T. A. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2020.10.013 · Cited by 12
Yu, X., Wang, Y., Lai, J., Song, T., & Duan, J. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-02988-x · Cited by 12
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Huang, H., Xie, J., Hou, L., Miao, M., Xu, L., & Xu, C. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14133 · Cited by 11
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 15
Lean MASLD and Cardiovascular Disease: A Review
Lebovics, N., Heering, G., Frishman, W. H., & Lebovics, E. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000893 · Cited by 11
Yang, A., Zhu, X., Zhang, L., Zhang, Y., Zhang, D., Jin, M., Niu, J., Zhang, H., Ding, Y., & Lv, G. (2022) · Hepatology International · doi:10.1007/s12072-022-10355-2 · Cited by 11
Petroni, M. L., Colosimo, S., Brodosi, L., Armandi, A., Bertini, F., Montesi, D., Bugianesi, E., & Marchesini, G. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17768 · Cited by 12
Duan, X., Lv, J., Jiang, H., Zheng, K., & Chen, Y. (2022) · Genetics Research · doi:10.1155/2022/8560831 · Cited by 11
Hu, S., Li, X., Sun, Y., Wu, S., Lan, Y., Chen, S., Wang, Y., Liao, W., Wang, X., Zhang, D., et al. (2022) · Obesity · doi:10.1002/oby.23459 · Cited by 11
Wang, K., Lin, W., Kuang, Z., Fan, R., Liang, X., Peng, J., Guo, Y., Chen, J., Liu, Z., Hu, X., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz326 · Cited by 11
Righetti, R., Cinque, F., Volpe, M. T., & Sebastiani, G. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2385487 · Cited by 10
Characterization of Nutrient Intake in Biopsy-Confirmed NAFLD Patients
Kamada, Y., Takahashi, K., Ogawa, Y., Hyogo, H., Nakamura, K., Yada, T., Asada, N., Bando, T., Sawano, H., Hatanaka, M., et al. (2022) · Nutrients · doi:10.3390/nu14173453 · Cited by 10
Navarro‐Masip, È., Petit, N. M., Zorzano-Martínez, M., Salinas‐Roca, B., Sánchez, E., López‐Cano, C., Herrerías, F., de la Fuente, M. C., Santamaría, M., León, J., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07071-1 · Cited by 10
Bilić-Ćurčić, I., Berković, M. C., Virovic-Jukic, L., & Mrzljak, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i1.80 · Cited by 6
Koo, D.-J., & Lee, W. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e17 · Cited by 9
Yuan, C., Zhang, C., Geng, X., Feng, C., Su, Y., Wu, Y., Wang, Y., Chen, L., Ding, Q., Voortman, T., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-20663-x · Cited by 9
Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs
Huang, X., Chen, H., Wen, S., Dong, M., Zhou, L., & Yuan, X. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s411400 · Cited by 9
Ruan, S., Yuan, X., Liu, J., Zhang, Q., & Ye, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s441641 · Cited by 9
Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis
Vuille‐Lessard, É., Lange, N. F., Riebensahm, C., Dufour, J., & Berzigotti, A. (2021) · Current Hepatology Reports · doi:10.1007/s11901-021-00563-z · Cited by 9
Guveli, H., Ozlu, T., Tasar, B. E., Kenger, E. B., & Eda, K. (2021) · Hepatology Forum · doi:10.14744/hf.2021.2021.0014 · Cited by 3
NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter
Alferink, L. J. M., & Murad, S. D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.024 · Cited by 8
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 7
Nutrition in MASLD: a patient focused, evidence-based clinician’s guide
Pekarska, K., Brennan, P. N., Wajcman, D. I., Towey, J., Cox, L., Weatherby, K., McPherson, S., Stine, J., Willemse, J., Li, W., et al. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103183 · Cited by 7
Tamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 10
Effect of Body Weight and Obesity on Esophageal Function
Yang, Y., Lin, J.-R., Li, Y., Wei, Y.-S., & Duan, Z. J. (2023) · Physiological Research · doi:10.33549/physiolres.935067 · Cited by 7
Voudouris, D., Horianopoulou, M., Apostolopoulou, Z., Chryssanthopοulos, C., Bardopoulou, M., Maridaki, M. D., Vassilakopoulos, T., Koutsilieris, M., & Philippou, Α. (2023) · Metabolites · doi:10.3390/metabo13101074 · Cited by 8
Azulai, S., Grinbaum, R., Beglaibter, N., Eldar, S. M., Rubin, M., Carmi, S., Schyr, R. B., Romano‐Zelekha, O., & Ben‐Zvi, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122724 · Cited by 9
Metadata
- Authors
- Wong, V. W.-S., Wong, G. L.-H., Chan, R. S.-M., Shu, S. S.-T., Cheung, B. H.-K., Li, L. S., Chim, A. M.-L., Chan, C. K.-M., Leung, J. K.-Y., Chu, W. C.-W., Woo, J., & Chan, H. L.-Y.
- Affiliations
- Chinese University of Hong Kong (HK)
- Corresponding author
- Chan, Henry Lik-Yuen
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 69
- Issue
- 6
- Pages
- 1349-1356
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2888552653
- Cited by
- 319
- References
- 35
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 62 · 2023: 54 · 2022: 40 · 2021: 45 · 2020: 31 · 2019: 18 · 2018: 1
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, non-obese patients, lifestyle intervention, physical activity, weight loss, intrahepatic triglyceride, waist circumference, predictors of treatment response, community-based patients, long-term follow-up, weight maintenance, 1H NMR
- MeSH terms
- Adult, Aged, Diet, Female, Follow-Up Studies, Humans, Life Style, Male, Middle Aged, Obesity, Prospective Studies, Remission Induction, Triglycerides, Weight Loss, Exercise, Body Mass Index, Single-Blind Method, Treatment Outcome, Waist Circumference, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review